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ABSTRACT
Cardiovascular disease (CVD) is a major cause of death in
smokers, particularly in those with chronic obstructive pul-
monary disease (COPD). Circulating endothelial progeni-
tor cells (EPC) are required for endothelial homeostasis,
and their dysfunction contributes to CVD. To investigate
EPC dysfunction in smokers, we isolated and expanded
blood outgrowth endothelial cells (BOEC) from peripheral
blood samples from healthy nonsmokers, healthy smokers,
and COPD patients. BOEC from smokers and COPD
patients showed increased DNA double-strand breaks and
senescence compared to nonsmokers. Senescence negatively
correlated with the expression and activity of sirtuin-1
(SIRT1), a protein deacetylase that protects against DNA
damage and cellular senescence. Inhibition of DNA damage
response by silencing of ataxia telangiectasia mutated
(ATM) kinase resulted in upregulation of SIRT1 expression
and decreased senescence. Treatment of BOEC from
COPD patients with the SIRT1 activator resveratrol or an
ATM inhibitor (KU-55933) also rescued the senescent phe-
notype. Using an in vivo mouse model of angiogenesis, we
demonstrated that senescent BOEC from COPD patients
are dysfunctional, displaying impaired angiogenic ability
and increased apoptosis compared to cells from healthy
nonsmokers. Therefore, this study identifies epigenetic reg-
ulation of DNA damage and senescence as pathogenetic
mechanisms linked to endothelial progenitors’ dysfunction
in smokers and COPD patients. These defects may contrib-
ute to vascular disease and cardiovascular events in smok-
ers and could therefore constitute therapeutic targets for
intervention. STEM CELLS 2013;31:2813–2826
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Endothelial progenitor cells (EPC) are circulating stem cells
that have the ability to differentiate into mature endothelial
cells, thereby contributing to postnatal vasculogenesis and
endothelial repair at sites of endothelial damage [1, 2]. Blood
outgrowth endothelial cells (BOEC, also called endothelial
colony forming cells [ECFC]), are a well-characterized endo-
thelial cell population with robust clonal proliferative poten-
tial and ability to form de novo vessels in vivo [3]. This
population has recently attracted considerable interest as a
potential cell-based therapy for vascular regeneration [4–6],
gene therapy [7, 8], and as a tool to study endothelial dys-
function in patients [9–12]. Endothelial progenitors contribute
to vascular homeostasis, thus their reduction or dysfunction
could be involved in the development of endothelial dysfunc-
tion and cardiovascular disease (CVD) [13–17].
Cigarette smoke-oxidative stress is a major risk factor for
CVD [18] and also the main risk factor for the development of
chronic obstructive pulmonary disease (COPD), an obstructive
lung inflammatory disorder affecting approximately 20% of
smokers [19]. Smokers with COPD are more likely to develop
CVD than smokers with normal lung function [20], and CVD
is the leading cause of death in COPD [21]. Numerous studies
have described endothelial dysfunction in young healthy
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smokers and in COPD patients [22, 23] and have suggested
that reduced numbers and dysfunction of EPC could contribute
to CVD in these groups [24–29]. However, the molecular pro-
cess that links smoking and COPD with CVD is still unclear.
DNA damage pathways are important contributors to aging
disorders, including COPD and CVD [30–34]. DNA damage,
caused by factors such as oxidative stress, activates ataxia
telangiectasia mutated (ATM) kinase, a key player in the DNA
damage response (DDR) [35, 36]; this can result in cell cycle
arrest, senescence, or apoptosis. Recent evidence shows
increased DNA damage and senescence in lung biopsies from
smokers and COPD patients [34, 37], which may contribute to
accelerated lung aging and pathogenesis of COPD [34, 38, 39].
Increased DNA damage and senescence is also evident in athero-
sclerotic plaques [33, 40]. Senescent vascular cells exhibit dys-
functional characteristics [33, 41, 42] and have been shown to
contribute to accelerated vascular aging and atherosclerosis [43].
Recent studies suggest that accumulation of DNA damage in
stem and tissue specific progenitor cells can result in senescence
and loss of their self-renewal ability, tissue aging, and/or stem
cell depletion [44–47]. Therefore, increased DNA damage is
currently considered a causative link in the development of
COPD, CVD, and tissue-specific stem cells aging.
An important regulator of genomic stability and cellular
senescence is Sirtuin-1 (SIRT1), a nicotinamide adenine dinu-
cleotide (NAD1)-dependent class III protein deacetylase [48].
SIRT1 is recruited to sites of DNA double-strand breaks
(DSB) induced by oxidative stress and is required for their
efficient repair and maintenance of genomic stability [49].
Cigarette smoke-oxidative stress has been shown to reduce
SIRT1 levels not only in vitro but also in lung tissue from
smokers and COPD patients [50, 51]. SIRT1 also inhibits
endothelial senescence and appears to have a prominent pro-
tective role in vascular cells [52, 53]. For these reasons,
SIRT1 is currently considered an important therapeutic target
for age-related disorders, including COPD and CVD [54–58].
The purpose of this study was to investigate whether EPC
are dysfunctional in smoking individuals and patients with
COPD due to increased DNA damage imposed by cigarette
smoke, which could contribute to the development of CVD
and to elucidate the pathways involved in this process.
MATERIALS AND METHODS
Participants
Blood samples (15–50 mL) were collected from healthy non-
smoking volunteers, smokers with normal lung function (forced
vital capacity in 1 second (FEV1) >80% predicted, FEV1/forced
vital capacity (FVC) >0.7), and COPD patients (FEV1<80% pre-
dicted, FEV1/FVC <0.7). All individuals (aged 38–80 years)
were free from significant cardiac, renal, hematological, or other
major disorders as determined by history, physical examination,
and screening investigations. All COPD patients were current or
ex-smokers and were classified according to the Global initiative
for chronic Obstructive Lung Disease (GOLD) criteria for sever-
ity of disease [19]. All volunteers were stable (no chest or other
infection requiring antibiotics and/or oral steroids) for at least 4
weeks. The study was approved by the Royal Marsden, Hammer-
smith and Queen Charlotte’s Ethics Committees, and informed
consent was obtained from all individuals.
Isolation and Culture of BOEC from Peripheral Blood
Peripheral blood mononuclear cells were isolated from blood sam-
ples and seeded at a density of 3–53 107 cells per well, in complete
endothelial growth medium (EGM)22 (Lonza, Walkersville, MD,
http://www.lonza.com), supplemented with 10% fetal bovine serum
(FBS) (Hyclone, Thermo Scientific, Fisher Scientific Ltd., Lough-
borough, U.K., http://www.hyclone.com), onto six-well plates pre-
coated with type I rat tail collagen (BD Biosciences, Bedford, MA,
http://www.bdbiosciences.com), as previously described [11, 59].
After 24 hours, nonadherent cells and debris were aspirated, adher-
ent cells were washed once with EGM-2 medium, and fresh EGM-2
was added to each well. Medium was changed daily for 7 days and
then every 2 days. Colonies of BOEC appeared between 7 and 22
days in culture as discrete colonies of cells with cobblestone mor-
phology and were enumerated by visual inspection using a 34
objective lens (Olympus microscope CKX41 and Olympus micro-
scope digital camera DP12-2, Olympus UK Ltd., London, U.K.,
http://www.olympus-global.com). Endothelial cells derived from
the colonies were passaged for 2–3 weeks after appearance and
grown to confluence.
In Vivo Matrigel Plug Assay
BOEC from nonsmokers and COPD patients were labeled with
the Vybrant DiI Cell-Labeling Solution (V-22885, Invitrogen
Ltd., Paisley, U.K., http://www.invitrogen.com), according to the
manufacturer’s protocol. BOEC (5 3 105) were mixed with 400
lL of Matrigel (BD Biosciences, 354234) and injected subcutane-
ously into the back or flank of NOD.CB17-Prkdcscid/NcrCrl
mice. Seven days later, the mice were sacrificed and the plugs
were harvested, frozen in liquid nitrogen, and cryosectioned.
Experiments were performed for each BOEC sample in duplicate.
Frozen sections were either fixed with 4% paraformaldehyde in
PBS at 4C overnight, and stained with hematoxylin and eosin
stain (H&E) or fixed with acetone at 4C for 10 minutes and ana-
lyzed by immunofluorescence confocal microscopy. Images for
H&E staining were taken with a BX50 camera (Olympus) with
Viewfinder software Version 3.0.1 (Pixera) using a 310 and 320
objective lenses. Images for immunofluorescence were captured
using a Zeiss LSM510 META confocal microscope (Carl Zeiss,
Welwyn Garden City, U.K., http://www.zeiss.com), using 320,
340, and 363 objective lenses and running version 3.2 of the
LSM acquisition software. At least three to five images were ana-
lyzed per sample. Volocity software (Improvision, Coventry,
U.K., http://www.improvision.com) was used for quantification of
cellular infiltration (H&E staining) and of Vybrant positive cells.
Senescence Induced by Oxidative Stress
A modified method of a previously described protocol [53] for
inducing premature senescence by H2O2 was used. Human umbili-
cal vein endothelial cells (HUVEC) or BOEC 1 3 105 were seeded
in six-well plates and grown to 80% confluence in M199 medium
(Sigma-Aldrich Company Ltd., Dorset, U.K., http://www.sigmaal-
drich.com) plus 10% FBS. Cells were washed twice with PBS and
treated for 1 hour with 25 lmol/L or 50 lmol/L of H2O2 (Sigma-
Aldrich Company Ltd.). Cells were washed twice with PBS and cul-
tured in M199 plus 10% FBS medium for two additional days.
RNA Interference
RNA interference of ATM and SIRT1 expression was induced by
small interference RNA (siRNA) from Dharmacon (ABgene Ltd.,
Surrey, U.K., http://www.abgene.com). Two siRNAs specific for
ATM with different sequences (siGENOME SMART-pool
Human ATM, M-003201-04-0005 and ON-TARGET plus Human
ATM, J-003201-14-0010), a siRNA specific for SIRT1 (ON-
TARGET plus SMART-pool Human SIRT1, L-03540-00-0005),
and two control siRNAs (siGENOME Non-Targeting siRNA
Pool, D-001206-14-05 and ON-TARGET plus Non-targeting
siRNA, D-001810-01-05) were used. Transfection of BOEC or
HUVEC was performed as previously described [11].
Immunofluorescence
Isolated BOEC or HUVEC were stained as previously described
[11] with antibodies to platelet endothelial cell adhesion molecule
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(PECAM) (CD31), vascular endothelial growth factor receptor
(VEGFR)22 (Abcam, Cambridge, U.K., http://www.abcam.com),
vascular endothelial (VE)-cadherin (CD144) (BD Bioscience Phar-
mingen Oxford, U.K., http://www.bdbiosciences.com/), von Wille-
brand factor (VWF) (Dako UK Ltd., Cambridge, U.K., http://
www.dako.com), CD45 (AbD Serotec, Oxford, U.K.), CD3 (Caltag
Laboratories, Buckingham, U.K.), p16 and p21 (Santa Cruz Bio-
technology, Insight Biotechnology Ltd., Wembley, U.K., http://
www.scbt.com), 53 binding protein 1 (53BP1) and c-H2AX (Cell
Signaling Technology, New England Biolabs, Hertfordshire, U.K.,
http://www.cellsignal.com). Secondary antibodies were anti-mouse
AlexaFluor 555 and anti-rabbit AlexaFluor 488 (Invitrogen Ltd.).
Nuclei were visualized using TOPRO-3 (Invitrogen Ltd.).
Frozen sections of Matrigel plugs were stained with antibod-
ies to CD31 (Abcam), p16 (Santa Cruz Biotechnology), 53BP1,
and cleaved caspase-3 (Cell Signaling Technology). Nuclei were
visualized using TOPRO-3 (Invitrogen Ltd.) or Draq-5 (Biostatus
Limited, Leicester, U.K.). Terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) staining was performed with
“In Situ Cell Death Detection Kit, Fluorescein” (Roche Diagnos-
tics Ltd., West Sussex, U.K., http://www.roche-applied-science.-
com). Images were captured by confocal microscopy as described
above.
Senescence-Associated b-Galactosidase Staining
Senescence-associated b-galactosidase (SA-b-Gal) activity was
measured with a b-Galactosidase staining kit (Senescence Detec-
tion Kit, BioVision Research Products, Mountain View, CA,
http://www.bioscience.co.uk) following the manufacturer’s proto-
col. The number of blue (senescent) cells relative to the total cell
number was counted in two to four different optic fields, using
310 or 320 objective lens. At least 200 cells were counted per
sample.
SIRT1 Activity Assay
Nuclear extracts were prepared using a nuclear extraction kit
(Active Motif Europe, Rixensart, Belgium, http://www.activemo-
tif.com). SIRT1 activity was measured using a SIRT1 fluorescent
activity assay kit (Fluor-de-Lys SIRT1 fluorometric drug discov-
ery assay kit, Enzo Life Sciences, Exeter, U.K., http://www.enzo-
lifesciences.com). Total SIRT1 activity and in the presence of a
sirtuin inhibitor (nicotinamide) were determined. SIRT1 activity
was calculated by subtracting nonspecific activity (activity in the
presence of nicotinamide) from the total SIRT1 activity and
expressed as lmol/L standard equivalent per lg protein.
Western Blotting
Western blotting was carried out as described [11]. The following
antibodies were used: SIRT1 (Cell Signaling Technology), ATM,
p21 (Santa Cruz Biotechnology), Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Millipore, Watford, U.K., http://
www.millipore.com), a-tubulin (Sigma-Aldrich Company Ltd.).
Quantification of protein levels was performed by densitometry
and normalized against GAPDH or a-tubulin.
Real-Time Polymerase Chain Reaction
RNA was extracted from HUVEC treated with siRNA for ATM or
control siRNA for 48 hours, as described [11]. Levels of SIRT1 nor-
malized to GAPDH mRNA were measured by quantitative real-time
polymerase chain reaction (RT-PCR) using the following primers to
SIRT1 (forward primer: 50-CGTCTTATCC TCTAGTTCTTGTG-30,
reverse primer: 50-ATCTCCATCAGTCC CAAATCC-30) and
GAPDH (forward primer: 50-CAAGGTCA TCCATGACAACTTTG-
30, reverse primer: 50-GGGCCATCCAC AGTCTTCTG-30).
Statistical Analysis
Data are expressed as means6 SEM. Statistical analysis was per-
formed with SPSS Version 20 (IBM, Armonk, NY). Comparisons
between multiple groups were performed using one-way ANOVA
followed by a Fisher’s least-significant difference post hoc test
for normally distributed data or Games-Howell test for non-
normally distributed data. Single comparisons were made with
Student’s t tests for normally distributed data or the Mann–Whit-
ney U test for data not normally distributed. The correlation of
values was estimated with the Spearman r correlation coefficient.
Significance was defined as a p value of <.05.
RESULTS
Isolation and Characterization of BOEC
Eighteen healthy nonsmokers, 11 smokers with normal lung
function, and 20 COPD patients were enrolled in the study
(for characteristics see Table 1). Cultures from all groups,
between day 7 and 22, gave rise to colonies of high prolifera-
tive potential, low proliferative potential, or no colonies at all
(Fig. 1A, 1B; Supporting Information Fig. 1A–1C). Colonies
appeared later in culture in healthy smokers compared to
Table 1. Clinical characteristics of volunteers
Characteristic Healthy nonsmokers Healthy smokers COPD
Number (n) 18 11 20 (3 mild, 12 moderate, 5 severe)a
Sex (M/F) 6/12 6/5 11/9
Age (years) 596 2 586 3 656 2
Smoking (pack-years) 0 356 7 516 4 (10 ex-smokers)
Lung function
FEV1, % predicted 97.66 3.6 91.26 2.1 62.16 3.5
b
FEV1/FVC, % predicted 75.96 1.4 73.76 2.0 53.86 2.7
b
Medication
Statins 3 2 3
Inhaled steroids 0 0 8
CVD comorbidities
Hypertension 2 0 1
Diabetes 0 0 1 (type 2)
Values are expressed as means6SEM.
aStaging of COPD is according to the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria.
bp < .001 (comparison between nonsmokers/smokers and COPD).
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEV1 and FEV1/
FVC ratio are postbronchodilator for subjects with COPD, smokers or nonsmokers; F, female; M, male; pack-years, number of packs ciga-
rettes smoked per day multiplied by the number of years of smoking.
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healthy nonsmokers (Supporting Information Fig. 1D). There
was no difference in the number of BOEC colonies per milli-
liter of blood between the three groups (Fig. 1B; Supporting
Information Fig. 1E). In two nonsmokers, five smokers and
six COPD patients BOEC isolation was performed twice,
since the first isolation procedure was unsuccessful. One
healthy nonsmoker was excluded from the analysis due to a
reduced white blood cell count of unknown etiology.
Colonies were expanded and gave rise to morphologically
homogeneous cultures (Supporting Information Fig. 1A–1C).
There was no difference in the number of days that the colonies
grew in culture before the first passage between the three
groups (Supporting Information Fig. 1F, 1G). BOEC from colo-
nies of high proliferative potential (expanded after passage 3)
were obtained from 11 out of 18 healthy nonsmoking, 7 out of
11 healthy smoking, and 14 out of 20 COPD volunteers and
were used for experiments between passage 3 and 6. The num-
ber of days between passage 2 and 3 (days6SEM) was:
2.56 0.2 in healthy nonsmokers, 4.66 1.1 in healthy smokers,
and 4.76 1 in COPD patients, indicating a slower growth rate
in healthy smokers and in COPD patients (even though signifi-
cant only in healthy smokers) compared to nonsmokers.
Figure 1. BOEC isolation and characterization. (A): Representative images of BOEC colonies in culture derived from healthy nonsmokers,
healthy smokers, and COPD patients. Immunofluorescence (IF) staining for VE-cadherin (red), VWF (green), and CD45 (red). TOPRO-3 (white)
was used as nuclear stain. BOEC from all groups were positive for the endothelial markers VE-cadherin and VWF and negative for the leuko-
cytic CD45 marker (bright-field images scale bars5 100 lm; IF images scale bars5 20 lm). (B): Number of BOEC colonies in healthy non-
smokers, healthy smokers, and patients with COPD. The number of discrete BOEC colonies that appeared in the peripheral blood mononuclear
cell culture was counted relative to the number of mL of blood obtained from healthy nonsmokers (n5 18), healthy smokers (n5 11), and
COPD patients (n5 20) (open triangle: ex-smokers, black triangle: current smokers). Abbreviations: BOEC, blood outgrowth endothelial cells;
COPD, chronic obstructive pulmonary disease; VWF, von Willebrand factor; VE, vascular endothelial.
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The endothelial lineage of the cells was confirmed as
described [11]. All samples were positive for a range of endo-
thelial cell markers including VE-cadherin, VWF, VEGFR-2,
and CD31 and were negative for the lymphocytic and leuko-
cytic markers CD3 and CD45 respectively (Fig. 1A; Support-
ing Information Fig. 2A–2C).
BOEC from Healthy Smokers and COPD Patients
Show Increased Senescence
Increased cellular senescence has been described in lung biop-
sies from COPD patients and in human atherosclerotic pla-
ques. BOEC from nonsmokers, healthy smokers, and COPD
patients were stained for SA-b-gal. BOEC from healthy
smokers and COPD patients displayed significantly increased
SA-b-gal activity compared to healthy nonsmokers (Fig. 2A).
We also measured p21 and p16 as alternative markers of
senescence. Expression of both p21 and p16 was increased in
BOEC from healthy smokers and COPD patients compared to
healthy nonsmokers (Fig. 2B–2D), confirming the increased
senescence in BOEC from healthy smokers and COPD
patients. There was no correlation between SA-b-gal activity
or p21 expression and age in all samples (Spearman r: .352,
p5 .06 and Spearman r: 2.133, p5 .7, respectively), indicat-
ing that the increased senescence observed in BOEC from
healthy smokers and COPD patients is age-independent.
DDR Is Increased in BOEC from Healthy Smokers
and COPD Patients
Activation of the ATM-dependent DNA damage signaling
pathway contributes to oxidative stress-induced premature
senescence in endothelial cells [60]. Mediators of DNA repair
via ATM activation are phosphorylated histone H2AX at serine
139 (c-H2AX) [61] and 53BP1 [62]; both mark the DSB in
DNA and appear as distinct nuclear foci by immunofluorescent
microscopy [36, 61, 62]. The presence of these foci can be
used to assess DNA damage and ATM activation, as shown in
HUVEC treated with H2O2, which induces oxidative-stress pre-
mature senescence [60] (Supporting Information Fig. 3A, 3B).
An increased number of BOEC with distinct c-H2AX and
53BP1 nuclear foci were observed in smokers and COPD
patients compared to healthy nonsmokers (Fig. 2E, 2F). In par-
ticular, 53BP1 foci were large and resembled the “53BP1
nuclear bodies” which have been shown to accumulate at chro-
mosomal fragile sites to protect them against erosion [62]. There
was no correlation between c-H2AX or 53BP1 and age in all
samples (Spearman r: .334, p5 .345 and Spearman r: .333,
p5 .318, respectively), indicating that the increased DNA dam-
age in BOEC from healthy smokers and COPD patients is age-
independent. Both c-H2AX and 53BP1 expression strongly cor-
related with SA-b-gal activity (Spearman r: 1.00, p < .0001 and
Spearman r: .95, p < .0001 respectively), as well as with smok-
ing pack-years (Table 1) in all groups (Spearman r: .9633, p <
.0001 and Spearman r: .8808, p5 .0003, respectively), suggest-
ing a causative link between DNA damage and senescence, pos-
sibly due to cigarette-smoke exposure.
SIRT1 Regulates Senescence in BOEC via
Deacetylation of p53; SIRT1 Protein Levels and
Activity Are Reduced In Healthy Smokers and
COPD Patients
Numerous studies describe the protective role of SIRT1
against endothelial senescence [53, 63–65], which we con-
firmed in HUVEC by inhibiting SIRT1 expression with RNA
interference. Treatment with siRNA for SIRT1 and control
siRNA was performed in baseline conditions as well as in
conditions of oxidative stress to induce premature senescence.
As expected, abrogation of SIRT1expression in HUVEC
resulted in increased senescence in both conditions (Support-
ing Information Fig. 4). We next confirmed the protective
role of SIRT1 against senescence in BOEC, as inhibition of
SIRT1 increased SA-b-gal activity in SIRT1-deficient BOEC
compared to control siRNA-treated cells, both in baseline and
oxidant conditions (Fig. 3A).
SIRT1 protein levels were significantly reduced in BOEC
from healthy smokers and COPD patients compared to
healthy nonsmokers (Fig. 3C). Similarly, SIRT1 activity was
significantly reduced in cells from healthy smokers and
COPD patients compared to healthy nonsmokers (Fig. 3D),
with a significant correlation between SIRT1 protein levels
and activity (Fig. 3E). No correlation between SIRT1 protein
levels or activity and age of the subjects was found (Spear-
man r: .01089, p5 .96 and Spearman r: 2.2038, p5 .42,
respectively). There was a significant negative correlation
between both SIRT1 protein levels and activity and SA-b-gal
staining in all samples (Fig. 3F, 3G), suggesting that reduced
SIRT1 expression was associated with the increased senes-
cence in BOEC from healthy smokers and COPD patients.
SIRT1 has been shown to inhibit senescence by targeting
p53, a transcription factor that becomes acetylated at Lys-382
as a result of DNA damage. This leads to enhanced p53 binding
to DNA and transcription of genes that cause cell cycle arrest,
senescence, or apoptosis [53, 66]. Inhibition of SIRT1 expres-
sion in BOEC, which caused increased senescence, also resulted
in increased acetylation of p53 at Lys-382, suggesting that the
protective effect of SIRT1 against senescence in BOEC may be
in part mediated by deacetylation of p53 (Fig. 3B).
Figure 2. Increased senescence and DNA damage in smokers and COPD patients. SA-b-gal activity, p21, and p16 were assessed as markers of
cellular senescence. (A): Quantification of SA-b-gal activity was assessed in blood outgrowth endothelial cells (BOEC) from healthy nonsmokers
(n5 10), healthy smokers (n5 6), and COPD patients (n5 12), by counting the number of blue (senescent) cells relative to the total cell number
and expressed as a percentage (%). BOEC from healthy smokers and COPD patients exhibited significantly increased senescence compared to
healthy nonsmokers. Representative images from a healthy nonsmoker (72 years old), a healthy smoker (64 years old), and a COPD patient (65
years old) are shown (scale bars5 100 lm). (B): p21 protein levels were measured by Western blotting in whole cell lysates from BOEC isolated
from healthy nonsmokers (n5 3), healthy smokers (n5 3), and COPD patients (n5 3). a-tubulin was used as loading control. p21 protein levels
were significantly increased in smokers and COPD patients compared to nonsmokers. Representative images of Western blots are shown. (C, D):
Immunofluorescence staining of BOEC for p16 (red, left panels) and p21 (red, right panels). TOPRO-3 (blue) was used as nuclear staining. Rep-
resentative images from the three groups are shown. (E, F): DNA damage was assessed by measuring two markers of DSB formation, the
c-H2AX (left panels) and 53BP1 (right panels) by immunofluorescence staining (n5 3–5). Representative images from the three groups are
shown. The number of cells with distinct nuclear immunofluorescent foci (see arrows) relative to the total cell number was counted in two to
four optic fields, using a 320 and 340 objective lens (scale bars5 20 lm). An increased number of cells with focal nuclear staining of c-H2AX
was observed in healthy smokers and COPD patients compared to healthy nonsmokers (E, bottom). An increased number of cells with focal
nuclear staining of 53BP1 was observed in healthy smokers and COPD patients compared to healthy nonsmokers (F, bottom). *, p < .05; **,
p < .01 (open triangle: ex-smokers, black triangle: current smokers). Abbreviations: COPD, chronic obstructive pulmonary disease; SA-b-gal,
senescence-associated-b-galactosidase; 53BP1, 53 binding protein 1.
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ATM Regulates SIRT1 Protein Expression and
Endothelial Senescence Induced by Oxidative Stress
SIRT1 is involved in ATM activation and downstream signal-
ing pathways promoting cell survival and DNA repair [67,
68] and in turn ATM regulates SIRT1 activity [69]. To test
whether ATM could also regulate SIRT1 levels, we inhibited
ATM expression by siRNA in HUVEC. Inhibition of ATM
caused a significant increase in SIRT1 mRNA and protein
levels and a reduction in SA-b-gal activity compared to con-
trol cells (Supporting Information Fig. 5; Fig. 4A). Silencing
of ATM also resulted in increased SIRT1 protein levels in
BOEC (Fig. 4B); however, its effect on senescence was mini-
mal because BOEC from healthy nonsmokers exhibited a
low-grade of baseline senescence (Fig. 4B).
We next examined whether regulation of SIRT1 and
senescence by ATM also applies under conditions of oxida-
tive stress, which induces DNA damage and premature endo-
thelial senescence and reduces SIRT1 protein levels [53]
(Supporting Information Fig. 3A–3C). Inhibition of ATM, in
H2O2-treated HUVEC induced a significant increase in SIRT1
protein levels and reduction in senescence compared to con-
trol siRNA-treated cells (Fig. 4C). The same mechanism was
confirmed in BOEC from healthy nonsmokers, where abroga-
tion of ATM expression by siRNA increased SIRT1 protein
levels and inhibited the oxidative stress-induced senescence
(Fig. 4D).
We next examined whether the same occurs in BOEC
from COPD patients, which display increased senescence in
baseline conditions. Interestingly, inhibition of ATM expres-
sion in BOEC from COPD patients upregulated SIRT1 levels
and reduced senescence (Fig. 5A), suggesting that SIRT1
upregulation through ATM inhibition could be a therapeutic
target in these patients.
SIRT1 Activators and ATM Inhibitors Reduce
Senescence in BOEC
SIRT1 activators like resveratrol and selective ATM inhibitors
like KU-55933 have been shown to reduce stress-induced pre-
mature senescence in HUVEC [60, 63]. Therefore, we tested
whether pharmacological treatment with SIRT1 activators and
ATM inhibitors could inhibit senescence in BOEC from COPD
patients. BOEC isolated from COPD patients were treated with
two different concentrations of resveratrol (Sigma-Aldrich
Company Ltd.) or KU-55933 (Calbiochem, Merck Chemicals
Ltd., Nottingham, U.K., http://www.merck.com). Treatment
with both doses of resveratrol and KU-55933 for 48 hours sig-
nificantly inhibited the increased senescence observed in BOEC
from COPD patients (Fig. 5B). In most cases, higher doses of
both resveratrol (50 lmol/L) and KU-55933 (10 lmol/L)
reduced the confluence of the cells, indicating possible toxicity
of these drugs at higher doses. We confirmed that the protective
effect of resveratrol against senescence is mediated by SIRT1
activation, as inhibition of oxidative stress-induced premature
senescence in SIRT1-deficient HUVEC and BOEC was abol-
ished by treatment with resveratrol (Supporting Information
Fig. 6). Our results indicate that SIRT1 activators and possibly
selective ATM inhibitors could be used therapeutically to
inhibit the increased senescence in circulating endothelial pro-
genitors in COPD patients with possible beneficial effects on
endothelial function and CVD.
BOEC from COPD Patients Show Reduced
Angiogenic Ability, and Increased DNA Damage,
Senescence and Apoptosis
BOEC exhibit in vivo angiogenic ability and form functional ves-
sels when in appropriate matrix and implanted into immunocom-
promised mice (mice with severe combined immunodeficiency
[SCID]) [3, 70, 71]. To test whether the in vitro BOEC dysfunc-
tion was reflected in vivo, we studied the in vivo angiogenic
capacity of these cells after injection into SCID mice. BOEC from
nonsmokers and COPD patients were labeled with the Vybrant
DiI Cell-Labeling Solution, mixed with Matrigel, and subcutane-
ously injected in SCID mice, as previously described [72]. Inter-
estingly, Matrigel plugs with BOEC from COPD patients showed
decreased cellular content and capillary-like structures compared
to healthy nonsmokers (Fig. 6A). An increased number of Vybrant
positive cells was found in the Matrigel plugs with BOEC from
nonsmokers compared to those with BOEC from COPD subjects
(Fig. 6B). Immunofluorescent analysis revealed lining and colocal-
ization of CD31 and Vybrant positive cells and formation of
capillary-like structures in the Matrigel plugs with BOEC from
nonsmokers but not in COPD samples (Fig. 6C).
Increased DDR and senescence (measured by expression
of 53BP1 and p16) was found in Vybrant positive cells in the
Matrigel plugs with BOEC from COPD patients compared to
nonsmokers (Fig. 6D, 6E), in line with the in vitro results.
Endothelial senescence is also linked to increased apoptosis
[73, 74] and oxidant conditions have been shown to induce
increased apoptosis and reduced tube-forming ability in
BOEC [75]. We therefore investigated the presence of apopto-
tic cells by staining for cleaved caspase-3 and TUNEL, and
found increased BOEC apoptosis in the COPD group com-
pared to nonsmokers (Fig. 6F, 6G). Therefore, the in vivo
data demonstrate that BOEC from COPD patients display
impaired angiogenic ability compared to nonsmokers, linked
to increased DNA damage, senescence, and apoptosis.
DISCUSSION
In this study, we demonstrate increased DNA damage and
senescence in progenitor cells of the endothelial lineage in
Figure 3. SIRT1 regulates senescence in blood outgrowth endothelial cells (BOEC); Decreased SIRT1 levels and activity in BOEC from
healthy smokers and COPD patients compared to healthy nonsmokers. (A, B): BOEC from healthy nonsmokers (n5 4) were transfected with
small interfering RNA (siRNA) against SIRT1 or control siRNA for 48 hours. Cells were exposed to 50 lmol/L H2O2 for 1 hour and cultured
for 48 additional hours to induce oxidative-stress premature senescence. Cellular senescence was assessed by SA-b-gal activity. Protein levels of
SIRT1 and acetylation of p53 at Lys-382 were measured by Western blotting. GAPDH was used as loading control. Inhibition of SIRT1 in
BOEC induced increased SA-b-gal activity and acetylation of p53 at Lys-382, both under baseline and oxidant conditions. (C): SIRT1 protein
levels were measured in BOEC from healthy nonsmokers (n5 9), healthy smokers (n5 6), and patients with COPD (n5 8) by Western blotting
(representative image shown). GAPDH was used as loading control. SIRT1 protein levels were significantly reduced in smokers and COPD
patients compared to nonsmokers. (D): SIRT1 activity was measured in nuclear extracts from BOEC isolated from healthy nonsmokers (n5 6),
healthy smokers (n5 6), and COPD patients (n5 7) using a SIRT1 fluorescent activity assay kit. SIRT1 activity was significantly reduced in
healthy smokers and COPD patients compared to healthy nonsmokers. (E–G): SIRT1 protein levels correlated with SIRT1 activity in samples
from all groups. SIRT1 protein levels and activity negatively correlated with SA-b-gal activity in samples from all groups (scale bars5 100 lm)
*, p < .05; **, p < .01; ***, p < .001. Abbreviations: COPD, chronic obstructive pulmonary disease; SA-b-gal senescence-associated-b-galacto-
sidase; SIRT1, sirtuin-1.
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smokers and COPD patients. This study provides strong evi-
dence of epigenetic alterations linked to cigarette smoke-
oxidative stress, demonstrating reduced SIRT1 expression via
the ATM mediated DDR pathway, and providing new insights
into the molecular mechanisms involved in endothelial dys-
function in smokers and COPD patients.
Increased DNA damage and senescence have previously
been shown in the peripheral lung of normal smokers and in
a greater degree in COPD patients compared to nonsmoking
controls [34, 37, 76]. This likely reflects the lung injury
induced by cigarette smoke-oxidative stress [38, 39, 77, 78].
Other studies show evidence of increased senescence and
telomere shortening in circulating white blood cells in smok-
ers and COPD patients [79–81], providing evidence for wide-
spread systemic cellular senescence and confirming the
proaging effects of smoking. In our study, we show for the
first time increased DNA damage and senescence in BOEC
from smokers and COPD patients compared to healthy non-
smokers, which were independent of the subjects’ age. There-
fore, our findings suggest accelerated aging of BOEC in
healthy smokers and COPD patients and possibly reflect a
systemic effect of cigarette smoke-oxidative stress on circulat-
ing endothelial progenitors. Interestingly, BOEC from smok-
ers and COPD patients, expanded in culture in nonoxidant
Figure 4. Inhibition of ATM signaling upregulates SIRT1 levels and suppresses endothelial senescence induced by oxidative stress. (A):
HUVEC were transfected with small interfering RNA (siRNA) against ATM or control siRNA and grown in low serum medium for 72 hours.
ATM and SIRT1 protein levels were measured by Western blotting. GAPDH was used as loading control. Cellular senescence was assessed by
SA-b-gal activity. SIRT1 protein levels were significantly increased (bottom left) and senescence was significantly reduced (bottom right) in
ATM-deficient cells compared to controls (n5 4–5). Representative images of Western blots and SA-b-gal activity are shown. (B): BOEC from
healthy nonsmokers were treated and assessed as described in panel (A). (C): After 48 hours of siRNA treatment for ATM and control, HUVEC
were exposed to 50 lmol/L H2O2 for 1 hour and cultured for 48 additional hours to induce oxidative-stress premature senescence. Inhibition of
ATM in HUVEC by siRNA induced increased SIRT1 protein levels (n5 3–6). ATM silencing also caused a reduction in SA-b-gal activity in
cells exposed to conditions of oxidative stress. Representative images of Western blots and SA-b-gal staining are shown. (D): BOEC from
healthy nonsmokers were treated and assessed as described in panel (C) to induce oxidative-stress premature senescence (scale bars5 100 lm) *,
p < .05; **, p < .01. Abbreviations: ATM, ataxia telangiectasia mutated; BOEC, blood outgrowth endothelial cells; HUVEC, human umbilical
vein endothelial cells; SA-b-gal senescence-associated-b-galactosidase; SIRT1, sirtuin-1.
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Figure 5. Inhibition of ATM suppresses senescence in blood outgrowth endothelial cells (BOEC) from COPD patients; treatment with SIRT1 acti-
vators and ATM inhibitors. (A): BOEC from COPD patients were transfected with siRNA and grown in low serum medium for 72 hours. SIRT1 and
ATM were measured by Western blotting and cellular senescence by SA-b-gal activity. SIRT1 protein levels were significantly increased (bottom
left), and senescence was significantly reduced (bottom right) in ATM-deficient BOEC (n5 3). Representative images of Western blots and SA-b-gal
staining are shown. (B): BOEC from COPD patients were seeded in basal medium (plus 10% fetal bovine serum) for 24 hours. BOEC were treated
with different concentrations of the SIRT1 activator RSV (10 and 50 lmol/L) or the selective ATM inhibitor KU (5 and 10 lmol/L) for 48 hours.
Treatment with both concentrations of RSV or KU significantly reduced the grade of senescence compared to control treated BOEC from COPD
patients (n5 4) (scale bars5 100 lm) *, p < .05; **, p < .01; ***, p < .001. Abbreviations: ATM, ataxia telangiectasia mutated; COPD, chronic
obstructive pulmonary disease; DMSO, Dimethyl sulfoxide; KU, KU-55933; RSV, resveratrol; SA-b-gal senescence-associated-b-galactosidase;
SIRT1, sirtuin-1.
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Figure 6. Senescent blood outgrowth endothelial cells (BOEC) from COPD patients show reduced angiogenic ability and increased apoptosis.
(A–G): BOEC from nonsmokers (n5 4) or COPD patients (n5 3) were labeled with Dil-Vybrant cell solution and were subcutaneously injected
in severe combined immunodeficiency mice. After 7 days, plugs were harvested, frozen, cryosectioned, and stained with hematoxylin and eosin
(H&E) (A) or analyzed by immunofluorescence microscopy (B, C). Experiments were performed for each sample in duplicate. Cellular infiltrate
was quantified in H&E sections (A, bottom) and Vybrant positive cells were quantified from Z-stack images taken with 320 objective lens
(B, right). (C): BOEC from nonsmokers formed capillary-like structures in the Matrigel plugs. Immunofluorescent analysis for CD31 staining
(green) revealed lining of the Vybrant positive cells and formation of capillary-like structures in the Matrigel plugs with BOEC from nonsmokers
but not in COPD samples. (D–G): Immunofluorescent analysis for p16 staining (green, top left), 53BP1 (green, top right), cleaved caspase-3
(green, bottom left), and TUNEL staining (green, bottom right) showed increased expression of all markers in BOEC from COPD patients com-
pared to nonsmokers (scale bars5 50 lm). Abbreviations: COPD, chronic obstructive pulmonary disease; 53BP1, 53 binding protein 1.
conditions, retained a senescent and dysfunctional phenotype.
Among the possible mechanisms responsible for this may be
transmission of the DNA damage to the daughter cells and/or
epigenetic alterations linked to increased senescence.
BOEC have been shown to contribute to endothelial homeo-
stasis and repair in areas of vascular damage, as they possess a
robust proliferative potential and can incorporate into and form
new blood vessels [82]. Several studies indicate that DNA dam-
age and endothelial senescence contribute to vascular dysfunc-
tion and the development of atherosclerosis [16, 17, 43, 83, 84].
BOEC have been shown to be sensitive to oxidative stress, and
when treated with oxidants they show reduced clonogenic
capacity, increased apoptosis, and reduced vessel formation in
vivo [75]. We demonstrated that BOEC from COPD patients
show reduced ability to form a capillary network in an in vivo
angiogenesis assay, which was also confirmed in BOEC from a
smoker volunteer (Supporting Information Fig. 7). Based on the
results of our study, we propose that circulating BOEC from
smokers and COPD patients, which show increased DNA dam-
age and senescence, are ineffective in repairing vascular dam-
age and maintaining vascular integrity and may be involved in
endothelial dysfunction in these groups, leading to an increased
severity of CVD.
The ATM mediated DDR pathway regulates cellular
senescence [30, 31, 60]. We showed that inhibition of the
ATM pathway results in upregulation of SIRT1 expression.
The protective role of SIRT1 overexpression against endothe-
lial senescence via deacetylation of p53 has been clearly dem-
onstrated in previous studies [53] and we also confirmed it in
BOEC. SIRT1 levels and activity are significantly decreased
in peripheral lung tissue and macrophages from COPD
patients, indicating a possible involvement of SIRT1 in the
pathogenesis of COPD [50, 51]. In this study, we observed
significantly lower levels of SIRT1 protein and activity in
BOEC from healthy smokers and COPD patients compared to
healthy nonsmokers. In all subjects, the levels of SIRT1 pro-
tein and activity negatively correlated with the grade of senes-
cence, suggesting that the increased BOEC senescence in
smokers and COPD patients could be linked to reduced
SIRT1 expression, secondary to cigarette smoke-induced oxi-
dative stress activation of ATM. Importantly, we showed that
the senescent phenotype of BOEC from smokers and COPD
patients can be reversed by the SIRT1 activator resveratrol or
an ATM inhibitor. Since ATM and SIRT1 proteins are cur-
rently targets for drug development, with compounds already
in clinical studies [85, 86], our data provides further rationale
for exploring the effects of these compounds in these patients.
Previous studies have found reduced numbers of circulat-
ing EPC in healthy smokers [26] and COPD patients [24, 27];
however, these findings were not confirmed by others [87,
88]. In our study, we did not find a difference in the number
of endothelial progenitors, measured as BOEC colonies per
milliliter blood, in healthy smokers or COPD group. The dis-
crepancy between studies may be due to the different cell
populations examined. Previous studies have assessed the
number of circulating EPC by measuring the endothelial cell-
colony forming units (EC-CFU) in mononuclear cell cultures,
or the number of mononuclear cells positive for CD34/
CD133/VEGFR-2 surface markers by flow cytometry. How-
ever, EC-CFU have been shown to represent a heterogeneous
population including myeloid cells which can express endo-
thelial characteristics in culture [89], while the CD34/CD133/
VEGFR2 positive subset of mononuclear cells was found to
be enriched with hematopoietic colony-forming cells that can-
not differentiate into mature endothelial cells in vitro or in
vivo [90]. Currently, there is no unique marker to identify cir-
culating EPC and, as Yoder and Ingram have suggested [82],
it might be helpful to avoid the term EPC and refer instead to
the specific cell population under investigation.
In our study, the majority of our COPD patients had mod-
erate disease (GOLD2). We did not recruit COPD patients
with very severe disease (GOLD4), hypoxemia, and other
major comorbidities, which could possibly have a further
impact on endothelium and on BOEC function. We also
excluded COPD patients and smokers with overt CVD, as
these subjects would be more likely to show abnormalities in
BOEC function. Even though it is important to see the effect
of all these factors on the endothelium, our aim in this study
was to identify the dysfunction imposed by cigarette smoke
on the endothelium with the least confounding factors, such
as hypoxia and the effect of medications. Future studies will
expand our work to involve COPD patients with more severe
disease and other co-morbidities, such as smokers with CVD.
CONCLUSION
In summary, we have provided evidence of increased DNA
damage and endothelial senescence in smokers and COPD
patients, processes that are known to increase the risk of ath-
erosclerosis and CVD. We have also identified a molecular
pathway whereby DNA damage and activation of ATM regu-
lates SIRT1 expression, suggesting a mechanism for DNA
damage-mediated endothelial senescence and dysfunction.
The use of circulating BOEC allows the investigation of
underlying molecular mechanisms affecting the endothelium.
The effect of cigarette smoke exposure on endothelial progen-
itors, which are thought to have regenerative properties for
the vascular system, provides a better understanding of the
CVD seen in smokers and patients with COPD.
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